



2017 Prior Authorization (PA) Criteria

Certain drugs require prior authorization from ConnectiCare VIP Medicare Plans. This means that your doctor must contact us to get approval before prescribing the drug to you. If your doctor does not get prior approval, the drug may not be covered.

This list also includes drugs that may be covered under Medicare Part B or Part D depending on how the drugs are used or administered. If your drug is on this list, your doctor should call us and to provide information describing the use and administration of the drug so we can advise on whether the drug will be covered.

To see if your drug is on the list, refer to the index located at the end of this document for the medication you are looking for or click this [\[SEARCH\]](#) button and enter the name of your drug in the pop-up task pane

.

ACTHAR

Products Affected

- Acthar H.P.

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Use in patients with multiple sclerosis (MS) as pulse therapy on a monthly basis.
Required Medical Information	MS exacerbation, history of corticosteroid use.
Age Restrictions	N/A
Prescriber Restrictions	Infantile spasms, prescribed by or in consultation with a neurologist or an epileptologist. MS exacerbation, prescribed by or in consultation with a neurologist or physician that specializes in the treatment of MS.
Coverage Duration	Infantile spasms, Plan Year. MS exacerbation, approve 1 month.
Other Criteria	For MS exacerbation, approve if the patient cannot use high-dose IV corticosteroids because IV access is not possible or if the patient has tried high-dose corticosteroids administered IV for an acute MS exacerbation and has experienced a severe or limiting adverse effect.



ACTIMMUNE

Products Affected

- Actimmune

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ADCIRCA

Products Affected

- Adcirca

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Nitrate therapy
Required Medical Information	PAH been confirmed by right heart catheterization.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ADEMPAS

Products Affected

- Adempas

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	PAH and CTEPH- must be prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	Plan Year
Other Criteria	For PAH - must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1). Right heart catheterization is not required in pts who are currently receiving Adempas or another agent indicated for WHO group 1.



AFINITOR

Products Affected

- Afinitor

- Afinitor Disperz

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Oncologist
Coverage Duration	Plan Year
Other Criteria	N/A

ALECENSA

Products Affected

- Alecensa

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Patients already started on Alecensa for a covered use
Exclusion Criteria	Xalkori (Crizotinib) treatment naive patients
Required Medical Information	Confirmed ALK-positive NSCLC as detected by an FDA-approved test and prior therapies tried
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan Year
Other Criteria	Anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC): The patient has metastatic ALK-positive NSCLC as detected by an FDA-approved test AND The patient has progressed on or are intolerant to Xalkori (crizotinib)

ALOSETRON

Products Affected

- alosetron

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D coverage
Exclusion Criteria	Patient has a history of any of the following conditions: Chronic or severe constipation or sequelae from constipation. Intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions. Ischemic colitis. Impaired intestinal circulation, thrombophlebitis or hypercoagulable state. Crohn's disease or ulcerative colitis. Diverticulitis. Severe hepatic impairment.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For diagnosis of severe diarrhea-predominant irritable bowel syndrome (IBS) alosetron is being prescribed for a woman AND chronic IBS symptoms have lasted at least 6 months AND gastrointestinal tract abnormalities have been ruled out AND the patient has had inadequate response to conventional therapy.

AMPYRA

Products Affected

- Ampyra

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus patient already started on dalfampridine extended-release for Multiple Sclerosis (MS).
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	MS. If prescribed by, or in consultation with, a neurologist or MS specialist.
Coverage Duration	Plan Year
Other Criteria	N/A



ANADROL

Products Affected

- Anadrol-50

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



ANTICONVULSANTS

Products Affected

- topiramate oral capsule, sprinkle
- topiramate oral capsule, sprinkle, ER 24hr
- topiramate oral tablet
- zonisamide

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



APOKYN

Products Affected

- APOKYN

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



APTIOM

Products Affected

- Aptiom

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ARCALYST

Products Affected

- Arcalyst

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus patient already started on rilonacept for Muckle Wells Syndrome (MWS) or Familial Cold Autoinflammatory Syndrome (FCAS).
Exclusion Criteria	Rilonacept should not be given in combination with biologic therapy (e.g. tumor necrosis factor (TNF) blocking agents (eg, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), anakinra, or canakinumab).
Required Medical Information	N/A
Age Restrictions	Initial tx CAPS-Greater than or equal to 12 years of age.
Prescriber Restrictions	Pending CMS approval
Coverage Duration	Plan Year
Other Criteria	CAPS renewal - approve if they have had a response and are continuing therapy to maintain response/remission.



AUBAGIO

Products Affected

- Aubagio

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

AVONEX

Products Affected

- Avonex (with albumin)
- Avonex intramuscular pen injector kit
- Avonex intramuscular syringe kit

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



BANZEL

Products Affected

- Banzel oral tablet

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

BOSULIF

Products Affected

- Bosulif

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D. Plus patients already started on Bosulif for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis for which Bosulif is being used. For chronic myelogenous leukemia (CML), the Philadelphia chromosome (Ph) status of the leukemia must be reported. For CML, prior therapies tried must be reported to confirm resistance or intolerance.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Pending CMS approval



BRIVIACT

Products Affected

- Briviact

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

CABOMETYX

Products Affected

- Cabometyx

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, medication history, histology, RET gene rearrangement status
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Advance Renal Cell Carcinoma-Patients must meet both 1 AND 2-1. Patient has RCC with predominant clear-cell histology 2. Patient has tried one tyrosine kinase inhibitor therapy (e.g., Sutent [sunitinib malate capsules], Votrient [pazopanib tablets], Inlyta [axitinib tablets], Nexavar [sorafenib tosylate tablets]).



CARBAGLU

Products Affected

- Carbaglu

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

CHOLBAM

Products Affected

- Cholbam

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	baseline liver function tests
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial approval for 3 months, continuation approval for plan year
Other Criteria	For continuation of therapy to be approved patient must meet 2 of the 3 following lab criteria or meet 1 of the 3 follow lab criteria and have body weight increased by 10% or stable at greater than the 50th percentile. Lab criteria: (1) patient alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 50 U/L or the baseline levels reduced by 80%, (2) patient total bilirubin level must be reduced to less than or equal to 1 mg/dL, (3) patient must not have evidence of cholestasis on liver biopsy.



CHORIONIC GONADOTROPINS (HCG)

Products Affected

- chorionic gonadotropin, human
- Novarel
- Pregnyl

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

CIALIS

Products Affected

- Cialis oral tablet 2.5 mg, 5 mg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Indication for which tadalafil is being prescribed.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Benign prostatic hyperplasia (BPH), after confirmation that tadalafil is being prescribed to treat the signs and symptoms of BPH and not for the treatment of erectile dysfunction (ED) and after a trial of an alpha-1 blocker (eg, doxazosin [Cardura XL], terazosin, tamsulosin [Flomax], alfuzosin extended-release [UroXatral]) or 5 alpha reductase inhibitor (eg, finasteride, dutasteride [Avodart]).

CINRYZE

Products Affected

- Cinryze

PA Criteria	Criteria Details
Covered Uses	Pending CMS approval
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Must be prescribed by, or in consultation with, an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders.
Coverage Duration	Plan Year
Other Criteria	N/A

COMETRIQ

Products Affected

- Cometriq

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D. Plus patients already started on Cometriq for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis of progressive, metastatic medullary thyroid cancer.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

COTELLIC

Products Affected

- Cotellic

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Previous therapies tried, presence of BRAF V600E or V600K mutation confirmed by an FDA approved test
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan Year
Other Criteria	Melanoma - being prescribed in combination with vemurafenib

CRINONE

Products Affected

- Crinone

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Use in patients to supplement or replace progesterone in the management of infertility.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

CYRAMZA

Products Affected

- Cyramza

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Previous therapies tried
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For gastric cancer or malignant neoplasm of cardio-esophageal junction of stomach, prior therapy with fluoropyrimidine- or platinum-containing therapy. For metastatic colorectal cancer, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) and prior therapy with Avastin (bevacizumab), oxaliplatin, and a fluoropyrimidine. For metastatic NSCLC, in combination with docetaxel and prior therapy with platinum-based chemotherapy. Part B versus D determination per CMS guidance.

DARAPRIM

Products Affected

- Daraprim

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D coverage
Exclusion Criteria	hypersensitivity to pyrimethamine, documented megaloblastic anemia due to folate deficiency
Required Medical Information	Concurrent drug regime
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Pending CMS approval

DARZALEX

Products Affected

- Darzalex

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Treatment-naive patients
Required Medical Information	History of previous treatments
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan Year
Other Criteria	For the treatment of Multiple myeloma treatment patients must have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or are double-refractory to a PI and an immunomodulatory agent.



DEMSEER

Products Affected

- Demser

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



DICLOFENAC GEL

Products Affected

- diclofenac sodium topical gel 3 %

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

DIGOXIN

Products Affected

- Digitek
- digoxin injection solution
- digoxin oral solution 50 mcg/mL
- digoxin oral tablet

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D coverage
Exclusion Criteria	N/A
Required Medical Information	Digoxin Level
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

EGRIFTA

Products Affected

- Egrifta subcutaneous recon soln 1 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis.
Age Restrictions	Adults
Prescriber Restrictions	Prescribed by or in consultation with an endocrinologist or a physician specializing in the treatment of HIV (eg, infectious disease, oncology).
Coverage Duration	Plan Year
Other Criteria	HIV-infected adult patients (18 years of age or older) with lipodystrophy AND Egrifta is being used to reduce excessive abdominal fat

EMPLICITI

Products Affected

- Empliciti

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Treatment-naive patients
Required Medical Information	History of previous treatments
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan Year
Other Criteria	For the treatment of multiple myeloma, patient must have received at least one prior therapy. Part B versus Part D determination will be made at time of prior authorization review per CMS guidance.

ENTRESTO

Products Affected

- Entresto

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Combination therapy with an ACE inhibitor/ACE inhibitor containing product, an ARB/ARB containing product, or Tekturna (aliskiren tablets) or a Tekturna-Containing Product in patients with diabetes
Required Medical Information	Must have LVEF less than or equal to 40 percent prior to initiation with Entresto
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, a cardiologist
Coverage Duration	Plan Year
Other Criteria	N/A

ERIVEDGE

Products Affected

- Erivedge

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus, patient already started on Erivedge for a covered use.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Locally advanced basal cell carcinoma (LABCC), approve if the patients BCC has recurred following surgery or the patient is not a candidate for surgery or radiation therapy.

ERWINAZE

Products Affected

- Erwinaze

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Documentation of hypersensitivity to Escherichia coli derived asparaginase as a component of a multi-agent chemotherapeutic regimen.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ESBRIET

Products Affected

- Esbriet

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Combination use with Nintedanib
Required Medical Information	N/A
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in combination with a pulmonologist
Coverage Duration	Plan Year
Other Criteria	IPF baseline -IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP.

EXTAVIA

Products Affected

- Extavia subcutaneous kit

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Concurrent use of any of the following medications: Interferon-beta therapy (Avonex, Betaseron, Extavia, or Rebif), mitoxantrone, fingolimod, teriflunomide, or dimethyl fumarate.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Patients with previous use (12 or more months) of Extavia must demonstrate one of the following clinical responses: decrease in the frequency of relapses, slowing of disease progression, MRI lesions have diminished with therapy, OR patient is stable on therapy.



FABRAZYME

Products Affected

- Fabrazyme intravenous recon soln 35 mg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



FARYDAK

Products Affected

- Farydak

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



FERRIPROX

Products Affected

- Ferriprox oral tablet

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

FIRAZYR

Products Affected

- Firazyr

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders.
Coverage Duration	Plan Year
Other Criteria	N/A



FYCOMPA

Products Affected

- Fycompa oral suspension
- Fycompa oral tablet

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

GATTEX

Products Affected

- Gattex One-Vial

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



GILOTRIF

Products Affected

- Gilotrif

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Pending CMS approval
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



GLATOPA/COPAXONE

Products Affected

- Copaxone subcutaneous syringe

- Glatopa

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent use of any of the following medications: Interferon-beta therapy (Avonex, Betaseron, Extavia, or Rebif), mitoxantrone, fingolimod, teriflunomide, or dimethyl fumarate.
Required Medical Information	Previous therapies tried
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan year
Other Criteria	Patients with previous use (12 or more months) of Glatopa/Copaxone must demonstrate one of the following clinical responses: decrease in the frequency of relapses, slowing of disease progression, diminished MRI lesions, OR patient is stable on therapy.



GROWTH HORMONE

Products Affected

- Norditropin FlexPro

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Pending CMS approval
Age Restrictions	For Turner syndrome and SGA, 2 years of age and older. For Noonan syndrome and SHOX, 3 years of age and older.
Prescriber Restrictions	Endocrinologist, Pediatric Nephrologist, Gastroenterologist, Nutritional Support Specialist, Infectious Disease Specialist
Coverage Duration	Plan Year
Other Criteria	N/A

HARVONI

Products Affected

- Harvoni

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent treatment with interferon, Sovaldi, Olysio, Daklinza, Technivie, Zepatier or Viekira
Required Medical Information	Prior to initiating therapy, detectable levels of HCV RNA in the serum. Genotype 1, 4, 5, 6. Cirrhosis documented by FibroScan, liver biopsy, or radiological imaging
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by or in consultation w/ GI, hepatologist, ID, or a liver transplant MD
Coverage Duration	12 wks or 24 wks as specified in Other Criteria.
Other Criteria	Criteria will be applied consistent with current AASLD/IDSA guidance

HETLIOZ

Products Affected

- HetlioZ

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For the indication of Non-24-Hour Sleep-Wake Disorder (Non-24), approval will only be granted for patients who are totally blind.

HRM

Products Affected

- benzotropine oral
- butalbital-acetaminop-caf-cod
- butalbital-acetaminophen
- butalbital-acetaminophen-caff oral capsule
- butalbital-acetaminophen-caff oral tablet 50-325-40 mg
- butalbital-aspirin-caffeine oral capsule
- clemastine oral tablet 2.68 mg
- cyclobenzaprine oral tablet
- cyproheptadine
- ergoloid
- meprobamate
- metaxalone
- methyldopa-hydrochlorothiazide
- promethazine oral tablet
- reserpine
- trihexyphenidyl

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Approve when the provider has assessed the risk versus benefit in using this High Risk Medication (HRM) in the patient and has confirmed that they would still like to initiate or continue therapy

HRM - BENZODIAZEPINES

Products Affected

- alprazolam oral tablet extended release 24 hr
- Lorazepam IntenSol
- lorazepam oral tablet
- oxazepam
- temazepam

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	Procedure-related sedation = 1mo. All other conditions = Plan Year.
Other Criteria	All medically accepted indications other than Restless Leg Syndrome and insomnia, authorize use. Restless Leg Syndrome, approve clonazepam if the patient has tried one other agent for this condition (eg, ropinirole, pramipexole, carbidopa-levodopa [immediate-release or extended-release]). Insomnia, approve lorazepam, oxazepam, or temazepam if the patient has had a trial with two of the following: ramelteon, trazodone, doxepin 3mg or 6 mg, eszopiclone, zolpidem, or zaleplon.

HRM BENZODIAZEPINES/ANTICONVULSANTS

Products Affected

- clonazepam oral tablet, disintegrating
- clorazepate dipotassium
- Diastat
- Diazepam Intensol
- diazepam oral solution 5 mg/5 mL (1 mg/mL)
- diazepam oral tablet
- diazepam rectal

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Approve when the provider has assessed the risk versus benefit in using this High Risk Medication (HRM) in the patient and has confirmed that they would still like to initiate or continue therapy

HRM PD

Products Affected

- amitriptyline
- clomipramine
- doxepin oral
- estradiol oral
- imipramine HCl
- imipramine pamoate
- megestrol oral tablet
- perphenazine-amitriptyline
- phenobarbital
- Surmontil
- trimipramine

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients aged less than 65 years, approve. Patients aged 65 years and older, other criteria apply.
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Approve when the provider has assessed the risk versus benefit in using this High Risk Medication (HRM) in the patient and has confirmed that they would still like to initiate or continue therapy



HYDROXYPROGESTERONE

Products Affected

- hydroxyprogesterone caproate

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



IBRANCE

Products Affected

- Ibrance

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



ICLUSIG

Products Affected

- Iclusig

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ILARIS

Products Affected

- Ilaris (PF)

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	When used in combination with concurrent biologic therapy (e.g. TNF antagonists, etanercept, adalimumab, certolizumab pegol, golimumab, infliximab), anakinra, or rilonacept.
Required Medical Information	N/A
Age Restrictions	CAPS-4 years of age and older. SJIA-2 years of age and older.
Prescriber Restrictions	Pending CMS approval
Coverage Duration	Plan Year
Other Criteria	For renewal of CAPS/MWS/FCAS - after pt had been started on Ilaris, approve if the pt had a response to therapy as determined by prescribing physician and the pt is continuing therapy to maintain a response/remission. For treatment of SJIA, initial therapy approve if the pt meets one of the following 1. has tried at least 2 other biologics for SJIA (tocilizumab, abatacept, TNF antagonists (e.g. etanercept, adalimumab, infliximab) OR 2. pt has features of poor prognosis (e.g. arthritis of the hip, radiographic damage, 6-month duration of significant active systemic disease, defined by fever, elevated inflammatory markers, or requirement for treatment with systemic glucocorticoids AND tried Actemra or Kineret. SJIA renewal approve if it patient was already started on Ilaris and the pt had a response (e.g. resolution of fever, improvement in limitations of motion, less joint pain or tenderness, decreased duration of morning stiffness or fatigue, improved function or ADLs, reduced dosage of CS) and the pt is continuing therapy to maintain response/remission.

IMATINIB/GLEEVEC

Products Affected

- Gleevec oral tablet 100 mg, 400 mg

- imatinib oral tablet 100 mg, 400 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) must be positive for the Philadelphia chromosome or BCR-ABL gene. For CML, patient meets one of the following: 1) newly diagnosed, 2) resistance or intolerance to prior therapy, or 3) recurrence after stem cell transplant. For ALL, patient meets one of the following: 1) newly diagnosed and Gleevec is used in combination with chemotherapy, or 2) ALL is relapsed or refractory. For GIST, patient meets one of the following: 1) unresectable, recurrent, or metastatic disease, or 2) use of Gleevec for adjuvant therapy following resection, or 3) use of Gleevec for pre-operative therapy and patient is at risk for significant surgical morbidity.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Approve Gleevec brand for those members with trial of imatinib for a covered use



IMBRUVICA

Products Affected

- Imbruvica

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	For patients with mantle cell lymphoma (MCL)-history of prior treatment.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

INLYTA

Products Affected

- Inlyta

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus, patients already started on Inlyta for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Advanced renal cell carcinoma, approve the patient has failed at least one prior systemic therapy (eg, Torisel, Avastin, Sutent, IFN-alpha, IL-2, Votrient, Nexavar).

IRESSA

Products Affected

- Iressa

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan Year
Other Criteria	Metastatic NSCLC - The patient has epidermal growth factor receptor (EGFR) exon 19 deletions OR has exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

IVIG

Products Affected

- Gammagard Liquid

- Gamunex-C injection solution 1 gram/10 mL (10 %)

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Authorization will be for Plan Year.
Other Criteria	Part B versus D determination per CMS guidance to establish if drug used for PID in pts home.

JAKAFI

Products Affected

- Jakafi oral tablet 10 mg, 15 mg, 20 mg, 25 mg, 5 mg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus, patients already started on Jakafi for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



JUXTAPID

Products Affected

- Juxtapid

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



KADCYLA

Products Affected

- Kadcyła intravenous recon soln 100 mg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	HER2 overexpression status. Prior therapies tried.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



KALYDECO

Products Affected

- Kalydeco

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

KEVEYIS

Products Affected

- Keveyis

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Patient with history of hypersensitivity to diclorphenamide or other sulfonamides, Patient on high dose aspirin, Patient with severe pulmonary disease, Patient with hepatic insufficiency
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Pending CMS approval
Coverage Duration	Initial therapy - 2 months, Continuing therapy - plan year

PA Criteria	Criteria Details
<p>Other Criteria</p>	<p>Hyperkalemic Periodic Paralysis (HyperPP) and Related Variants: Patient has a confirmed diagnosis of primary hyperkalemic periodic paralysis by meeting at least ONE of the following criteria: Patient has had an increase from baseline in serum potassium concentration of greater than or equal to 1.5 mEq/L during a paralytic attack OR Patient has had a serum potassium concentration during a paralytic attack of greater than 5.0 mEq/L OR Patient has a family history of the condition OR Patient has a genetically confirmed skeletal muscle sodium channel mutation AND The prescribing physician has excluded other reasons for acquired hyperkalemia (e.g., drug abuse, renal and adrenal dysfunction) For Continuation of treatment a patient has decrease in the frequency or severity of paralytic attacks with treatment as determined by the prescribing physician. For Hypokalemic Periodic Paralysis (HypoPP) and Related Variants for Initiation of treatment: Patient has a confirmed diagnosis of primary hypokalemic periodic paralysis by meeting at least ONE of the following: Patient has had a serum potassium concentration of less than 3.5 mEq/L during a paralytic attack OR Patient has a family history of the condition OR Patient has a genetically confirmed skeletal muscle calcium or sodium channel mutation AND Patient has had improvements in paralysis attack symptoms with potassium intake. For Continuation of treatment: Patient has decrease in the frequency or severity of paralytic attacks with treatment as determined by the prescribing physician</p>



KEYTRUDA

Products Affected

- Keytruda

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	For NSCLC, PD-L1 status and prior therapies tried.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



KORLYM

Products Affected

- Korlym

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

KUVAN

Products Affected

- Kuvan oral tablet, soluble

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Blood phenylalanine (Phe) levels. Pretreatment blood phenylalanine (Phe) levels greater than 10mg/dL if the patient is older than 12 years of age or greater than 6mg/dL if less than or equal to 12 years of age. Response to a therapeutic trial (greater than or equal to a 30% reduction in blood Phe levels) is required for long-term authorization.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Pending CMS approval
Other Criteria	Blood Phe levels should be checked after 1 week of therapy and periodically up to one month during a therapeutic trial.



KYNAMRO

Products Affected

- Kynamro

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Current LDL-C (within the past 30 days), prior therapies tried
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For HoFH approve after trial of Repatha.



LENVIMA

Products Affected

- Lenvima

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

LETAIRIS

Products Affected

- Letairis

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Pregnancy
Required Medical Information	Pending CMS approval
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	UD or two appropriate contraceptive methods will be used for women of childbearing potential.

LEUKINE

Products Affected

- Leukine injection recon soln

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Administration within 24 hours preceding or following chemotherapy or radiotherapy, hypersensitivity to yeast-derived products. For prophylaxis of febrile neutropenia: use to increase the chemotherapy dose intensity or dose schedule above established regimens. For treatment of febrile neutropenia, when patient receives Neulasta during the current chemotherapy cycle. For AML only, excessive (greater than or equal to 10%) leukemic myeloid blasts in the bone marrow or peripheral blood.
Required Medical Information	For patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy: Leukine may be used for the prevention of chemotherapy-induced febrile neutropenia if the patient experienced febrile neutropenia with a prior chemotherapy cycle OR the patient is at risk of developing febrile neutropenia. Leukine is allowable for the treatment of febrile neutropenia in patients who have received prophylaxis with Leukine (or Neupogen) OR in patients at risk for infection-related complications.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	N/A

LEUPROLIDE

Products Affected

- Eligard
- Lupron Depot
- Lupron Depot (3 Month)
- Lupron Depot (4 Month)
- Lupron Depot (6 Month)
- Lupron Depot-Ped intramuscular kit 11.25 mg, 15 mg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D but specific to the following drugs as follows: Prostate cancer (Lupron Depot [7.5 mg-1mo, 22.5 mg-3-mo, 30 mg-4-mo, 45 mg-6-mo] OR Eligard [7.5 mg-1-mo, 22.5mg-3-mo, 30 mg-4-mo, 45 mg-6-mo]), Endometriosis (Lupron Depot [3.75 mg-1-mo, 11.25 mg-3-mo]), Uterine leiomyomata (Lupron Depot [3.75 mg-1-mo, 11.25 mg-3-mo]), Treatment of central precocious puberty (Lupron Depot Ped [11.25 mg-1-mo, 15 mg-1-mo]). Ovarian cancer (Lupron Depot [7.5 mg-1-mo]). Breast cancer (Lupron Depot [3.75 mg-1-mo, 11.25 mg-3-mo]). Prophylaxis or treatment of uterine bleeding in premenopausal women with hematologic malignancy or prior to bone marrow/stem cell transplantation (BMT/SCT) (Lupron Depot [3.75 mg-1-mo, 7.5 mg-1-mo]).
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	For abnrml uterine bleeding, uterine leiomyomata,endometriosis-6 mo.All other=Plan Year
Other Criteria	N/A



LIDOCAINE PATCH

Products Affected

- lidocaine topical adhesive patch,medicated

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus diabetic neuropathic pain.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



LINEZOLID

Products Affected

- linezolid

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Culture and sensitivity and CBC within normal limits
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	28 days
Other Criteria	N/A

LONSURF

Products Affected

- Lonsurf

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	Treatment-naive patients
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan year
Other Criteria	For Metastatic colorectal cancer, patient must have previously been treated with a fluoropyrimidine (e.g., capecitabine, 5-FU) AND oxaliplatin AND irinotecan AND an anti-VEGF therapy And if RAS wild type, an anti-EGFR therapy.



LYNPARZA

Products Affected

- Lynparza

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



MEGESTROL

Products Affected

- megestrol oral suspension 400 mg/10 mL (40 mg/mL), 625 mg/5 mL

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



MEKINIST

Products Affected

- Mekinist

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Documentation of the detected BRAFV600E or BRAFV600K mutation
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



METHAMPHETAMINE

Products Affected

- methamphetamine

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

NAMENDA

Products Affected

- memantine
- Namenda
- Namenda Titration Pak
- Namenda XR

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Approval can be given for brand name Namenda immediate release for patient who have a trial of memantine immediate release for a covered use.

NATPARA

Products Affected

- Natpara

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Hypoparathyroidism caused by calcium-sensing receptor mutations. Patients with acute post-surgical hypoparathyroidism.
Required Medical Information	Serum calcium level
Age Restrictions	18 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	Plan year
Other Criteria	For diagnosis of hypocalcemia in patients with hypoparathyroidism, documentation required to show hypocalcemia is not corrected by calcium supplements and active forms of vitamin D alone.

NEUPOGEN

Products Affected

- Neupogen

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Administration within 24 hours preceding or following chemotherapy or radiotherapy, E coli hypersensitivity. For prophylaxis of febrile neutropenia: use to increase the chemotherapy dose intensity or dose schedule beyond established regimen. For treatment of febrile neutropenia, when patient receives Neulasta during the current chemotherapy cycle.
Required Medical Information	For patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy: Neupogen may be used for the prevention of chemotherapy-induced febrile neutropenia if the patient experienced febrile neutropenia with a prior chemotherapy cycle OR the patient is at risk of developing febrile neutropenia. Neupogen is allowable for the treatment of febrile neutropenia in patients who have received prophylaxis with Neupogen (or Leukine) OR in patients at risk for infection-related complications.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	6 months
Other Criteria	N/A



NEUPRO

Products Affected

- Neupro

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan year
Other Criteria	N/A

NEXAVAR

Products Affected

- Nexavar

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Combination with carboplatin and paclitaxel in patients with squamous cell lung cancer
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Oncologist
Coverage Duration	Plan Year
Other Criteria	N/A

NINLARO

Products Affected

- Ninlaro

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Previous therapies tried and failed, baseline CBC
Age Restrictions	18 years and older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan Year
Other Criteria	For multiple myeloma, patient has received at least one prior therapy AND will be used in combination with lenalidomide and dexamethasone.



NORTHERA

Products Affected

- Northera

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Initial 4 weeks, renewal 6 months
Other Criteria	N/A



NUPLAZID

Products Affected

- Nuplazid

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



NUVIGIL/PROVIGIL

Products Affected

- modafinil

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	Patients must be greater than or equal to 17 years of age.
Prescriber Restrictions	N/A
Coverage Duration	Plan year
Other Criteria	Excessive sleepiness due to SWSD if the patient is working at least 5 overnight shifts per month.



OCTREOTIDE

Products Affected

- octreotide acetate injection solution

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ODOMZO

Products Affected

- Odomzo

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan year
Other Criteria	For locally advanced basal cell carcinoma (BCC) has recurred following surgery or radiation therapy or if the patient is not a candidate for surgery and the patient is not a candidate for radiation therapy, according to the prescribing physician.

OFEV

Products Affected

- Ofev

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Combination use with pirfenidone
Required Medical Information	N/A
Age Restrictions	18 years of age and older
Prescriber Restrictions	Prescribed by or in combination with a pulmonologist
Coverage Duration	Plan Year
Other Criteria	IPF baseline - IPF must be diagnosed with either findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP) or surgical lung biopsy demonstrating UIP.

ONFI

Products Affected

- Onfi oral suspension
- Onfi oral tablet 10 mg, 20 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	The patient will receive Onfi for the treatment of seizures associated with Lennox-Gastaut syndrome.
Age Restrictions	2 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

OPDIVO

Products Affected

- Opdivo intravenous solution 40 mg/4 mL

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	For NSCLC, EGFR or ALK status. Prior therapies tried
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For NSCLC, patient must have prior platinum-based chemotherapy or FDA-approved therapy for EGFR or ALK aberrations. For RCC, patient must have prior antiangiogenic therapy.

OPSUMIT

Products Affected

- Opsumit

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	PAH WHO group, right heart catheterization
Age Restrictions	N/A
Prescriber Restrictions	PAH - must be prescribed by or in consultation with a cardiologist or a pulmonologist.
Coverage Duration	Plan Year
Other Criteria	<p>Pulmonary arterial hypertension (PAH) WHO Group 1 patients not currently on Opsumit or another agent indicated for WHO Group 1 PAH are required to have had a right-heart catheterization to confirm the diagnosis of PAH to ensure appropriate medical assessment. PAH WHO Group 1 patients currently on Opsumit or another agent indicated for WHO Group 1 PAH may continue therapy without confirmation of a right-heart catheterization. For patients not currently on Opsumit with confirmed diagnosis of PAH, approval will be given after a trial of Letairis, unless contraindicated.</p>

ORKAMBI

Products Affected

- Orkambi

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Combination use with Kalydeco
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	CF - homozygous for the Phe508del (F508del) mutation in the CFTR gene (meaning the patient has two copies of the Phe508del mutation)



PEGASYS

Products Affected

- Pegasys subcutaneous solution
- Pegasys subcutaneous syringe

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

PEGINTRON

Products Affected

- PegIntron

- PegIntron Redipen

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Decompensated liver disease. Autoimmune hepatitis. Concomitant administration of didanosine with ribavirin in patients coinfectd with HIV.
Required Medical Information	HCV: Prior to initiating therapy, detectable levels of HCV RNA in the serum.
Age Restrictions	N/A
Prescriber Restrictions	ID specialist, Gastroenterologist, Oncologist
Coverage Duration	Plan Year
Other Criteria	Monitor for evidence of depression.



PENICILLAMINE

Products Affected

- Depen Titratabs

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan year
Other Criteria	N/A

PERJETA

Products Affected

- Perjeta

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	HER2 overexpression status.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For breast cancer and metastatic breast cancer, must be used in combination with trastuzumab and docetaxel.



PHENOXYBENZAMINE

Products Affected

- phenoxybenzamine

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

POMALYST

Products Affected

- Pomalyst

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Pregnancy
Required Medical Information	For active myeloma, patient meets the following: 1) Pomalyst is used after at least two prior therapies or as salvage therapy. 2) Pomalyst may be used with dexamethasone. For female patients of childbearing potential, pregnancy is excluded by 2 negative serum or urine pregnancy tests. For all patients, complete blood counts are monitored for hematologic toxicity while receiving Pomalyst.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Male and female patients of child-bearing potential should be instructed on the importance of proper utilization of appropriate contraceptive methods for Pomalyst use. Patients should be monitored for signs and symptoms of thromboembolism.



POTIGA

Products Affected

- Potiga

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

PRALUENT

Products Affected

- Praluent Pen subcutaneous pen injector 150 mg/mL, 75 mg/mL
- Praluent Syringe subcutaneous syringe 150 mg/mL, 75 mg/mL

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent use of Praluent with Repatha, Juxtapid or Kynamro.
Required Medical Information	Current LDL-C (within the past 30 days), prior therapies tried, medication adverse event history
Age Restrictions	18 years of age and older.
Prescriber Restrictions	Prescribed by, or in consultation with, a cardiologist, endocrinologist, or a physician who focuses in the treatment of CV risk management and/or lipid disorders
Coverage Duration	Plan Year

PA Criteria	Criteria Details
<p>Other Criteria</p>	<p>Hyperlipidemia in pts w/ (ASCVD) apprv if the pt has a curr LDL-C lvl of grtr or eq to 70 mg/dL w/in the past 30 ds (after tx with antihyperlipidemic agnts but prior to PCSK9 inh tx such as Praluent or Repatha) AND the pt has had one of the following conds or dxs: prev MI,OR has a hx of an acute coronary syndrome, OR The pt has a dx of angina (stable or unstable) ,OR The pt has a past hx of stroke or TIA, OR The pt has PAD, The pt has undergone a coronary or other arterial revascularization procedure AND The pt has tried 1 high-intensity statin tx (i.e., atorvastatin 80 mg daily or Crestor 40 mg daily) for equal or more than 12 cont wks AND the LDL-C lvl remains equal or more than 70 mg/dL unless pt experienced statin-related rhabdomyolysis, OR the pt experienced skeletal-related muscle symptoms while receiving separate trials of atorvastatin and Crestor and during both trials the skeletal-related symptoms resolved during d/c. AND If pt able to tolerate statins cont to rec. the max tolerated dose of a statin while rec. Praluent tx. Heterozygous Familial Hypercholesterolemia apprve if the pt has a curnt LDL-C lvl eq or more than 100 mg/dL w/in the past 30 days, AND the pts dx of HeFH is def as probable or definite by WHO/Dutch Lipid grp criteria OR definite by Simon-Broome Criteria OR genetic testing, AND The pt has tried 1 high-intensity statin txs (i.e., atorvastatin 80 mg daily or Crestor 40 mg daily) for equal or more than 12 cont wks, AND the LDL-C lvl remains eq or more than 100 mg/dL, unless pt experienced statin-related rhabdomyolysis, OR the pt experienced skeletal-related muscle symptoms while receiving separate trials of atorvastatin and Crestor and during both trials the skeletal-related symptoms resolved during d/c. AND If pt able to tolerate statins cont to rec. the max tolerated dose of a statin while rec. Praluent tx.</p>

PROCRIT

Products Affected

- Procrit injection solution 10,000 unit/mL, 2,000 unit/mL, 20,000 unit/mL, 3,000 unit/mL, 4,000 unit/mL, 40,000 unit/mL

PA Criteria	Criteria Details
Covered Uses	Pending CMS approval
Exclusion Criteria	N/A
Required Medical Information	Pending CMS approval
Age Restrictions	MDS anemia/HepC anemia = 18 years of age and older
Prescriber Restrictions	Pending CMS approval
Coverage Duration	Anemia w/myelosuppress = 4 mos. Transfus=1 mo. Other= 6mo. HIV + zidovudine = 4 mo
Other Criteria	Part B versus Part D determination will be made at time of prior authorization review per CMS guidance to establish if the drug prescribed is to be used for an end-stage renal disease (ESRD)-related condition.

PROLIA

Products Affected

- Prolia

PA Criteria	Criteria Details
Covered Uses	Pending CMS approval
Exclusion Criteria	Concomitant use with other medications for osteoporosis (eg, denosumab [Prolia], other bisphosphonates, raloxifene, calcitonin nasal spray [Miacalcin, Fortical]), except calcium and Vitamin D.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Pending CMS approval

PROMACTA

Products Affected

- Promacta

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Thrombocytopenia due to hepatitis C virus (HCV)-related cirrhosis.
Exclusion Criteria	Use in the management of thrombocytopenia in myelodysplastic syndrome (MDS). Use in combination with Nplate for treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia purpura.
Required Medical Information	Pending CMS approval
Age Restrictions	N/A
Prescriber Restrictions	Pending CMS approval
Coverage Duration	Plan Year
Other Criteria	Thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia purpura, approve if the patient has tried corticosteroids or IVIG or has undergone a splenectomy. Treatment of thrombocytopenia due to HCV-related cirrhosis, approve to allow for initiation of antiviral therapy if the patient has low platelet counts (eg, less than 75,000 mm ³) and the patient has chronic HCV infection and is a candidate for hepatitis C therapy .

QUININE

Products Affected

- quinine sulfate

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan year
Other Criteria	N/A



RAVICTI

Products Affected

- Ravicti

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

REBIF

Products Affected

- Rebif (with albumin)
- Rebif Rebidose subcutaneous pen injector 22 mcg/0.5 mL, 44 mcg/0.5 mL, 8.8mcg/0.2mL-22 mcg/0.5mL (6)
- Rebif Titration Pack

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

REMICADE

Products Affected

- Remicade

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Active infection (including TB), concurrent use with other biologics, unstable moderate to severe HF (NYHA Functional Class III/IV).
Required Medical Information	<p>Screening for latent TB infection and assessment for Hep B risk. For positive latent TB, patient must have completed treatment or is currently receiving treatment for LTBI. HBV infection ruled out or treatment initiated for positive infection. Rheumatoid arthritis - An inadequate response or intolerance to Enbrel or Humira and one of the following: 1) inadequate response to methotrexate (MTX), 2) inadequate response to another nonbiologic DMARD (e.g., leflunomide, hydroxychloroquine, sulfasalazine) if contraindicated or intolerant to MTX, 3) intolerance or contraindication to 2 nonbiologic DMARDs. Psoriatic arthritis with predominantly peripheral symptoms - Must meet both of the following: 1) have an inadequate response or intolerance to either Enbrel or Humira, and 2) have an inadequate response to at least an 8-week maximum tolerated dose trial of at least 1 nonbiologic DMARD unless contraindicated or intolerant to such therapy. For plaque psoriasis - More than 10% BSA affected or has crucial body areas (e.g., feet, hands, face) affected. An inadequate response to at least a 60-day trial of 2 conventional therapies (e.g., phototherapy, calcipotriene, MTX, acitretin) unless contraindicated or intolerant to such therapies. Crohn's disease - Must meet both of the following: 1) have an inadequate response to at least a 60-day trial of 1 conventional therapy (e.g., corticosteroids, sulfasalazine, azathioprine, mesalamine) unless contraindicated or intolerant to such therapy, and 2) have an inadequate response or intolerance to either Humira or Cimzia. Ulcerative colitis - An inadequate response to at least a 60-day trial of 2 conventional therapies (e.g., corticosteroids, mesalamine) unless contraindicated or intolerant to such therapies.</p>
Age Restrictions	For plaque psoriasis, patient must be 18 years of age and older.
Prescriber Restrictions	N/A
Coverage Duration	Initial: 3 months for Crohn's disease and UC, plan year for all others. Renewal: plan year

PA Criteria	Criteria Details
Other Criteria	For continuation of therapy, patient's condition must have improved or stabilized.

REPATHA

Products Affected

- Repatha SureClick

- Repatha Syringe

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent use of Repatha with Praluent, Juxtapid or Kynamro
Required Medical Information	Current LDL-C (within the past 30 days), prior therapies tried, medication adverse event history
Age Restrictions	ASCVD/HeFH - 18 yo and older, HoFH 13 yo and older.
Prescriber Restrictions	Prescribed by, or in consultation with, a cardiologist, endocrinologist, or a physician who focuses in the treatment of CV risk management and/or lipid disorders
Coverage Duration	Plan Year

PA Criteria	Criteria Details
<p>Other Criteria</p>	<p>Hyperlipidemia in pts w/ (ASCVD) apprv if the pt has a curr LDL-C lvl of grtr or eq to 70 mg/dL w/in the past 30 ds (after tx with antihyperlipidemic agnts but prior to PCSK9 inh tx such as Praluent or Repatha) AND the pt has had one of the following conds or dxs: prev MI,OR has a hx of an acute coronary syndrome, OR The pt has a dx of angina (stable or unstable) ,OR The pt has a past hx of stroke or TIA, OR The pt has PAD, The pt has undergone a coronary or other arterial revascularization procedure AND The pt has tried 1 high-intensity statin tx (i.e., atorvastatin 80 mg daily or Crestor 40 mg daily) for equal or more than 12 cont wks AND the LDL-C lvl remains equal or more than 70 mg/dL unless pt experienced statin-related rhabdomyolysis, OR the pt experienced skeletal-related muscle symptoms while receiving separate trials of atorvastatin and Crestor and during both trials the skeletal-related symptoms resolved during d/c. AND If pt able to tolerate statins cont to rec. the max tolerated dose of a statin while rec. Repatha tx. Heterozygous Familial Hypercholesterolemia apprve if the pt has a curnt LDL-C lvl eq or more than 100 mg/dL w/in the past 30 days, AND the pts dx of HeFH is def as probable or definite by WHO/Dutch Lipid grp criteria OR definite by Simon-Broome Criteria OR genetic testing, AND The pt has tried 1 high-intensity statin txs (i.e., atorvastatin 80 mg daily or Crestor 40 mg daily) for equal or more than 12 cont wks, AND the LDL-C lvl remains eq or more than 100 mg/dL, unless pt experienced statin-related rhabdomyolysis, OR the pt experienced skeletal-related muscle symptoms while receiving separate trials of atorvastatin and Crestor and during both trials the skeletal-related symptoms resolved during d/c. AND If pt able to tolerate statins cont to rec. the max tolerated dose of a statin while rec. Repatha tx. HoFH - approve if meets all of the following has one of the following genetic confirmation of two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus AND LDL-C lvl grtr or eq to 100 mg/dL within the past 30 ds AND tried 1 high-intensity statin therapystatin tx (i.e., atorvastatin 80 mg daily or Crestor 40 mg daily) for equal or more than 12 cont wks AND the LDL-C lvl remains equal or more than 100 mg/dL unless pt experienced statin-related rhabdomyolysis, OR the pt experienced skeletal-related muscle symptoms while receiving separate trials of atorvastatin and Crestor and during both trials the skeletal-related symptoms resolved during d/c. AND If pt able to tolerate statins cont to rec. the max tolerated dose of a statin while rec. Repatha tx.</p>



REVATIO

Products Affected

- sildenafil oral

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Nitrate therapy
Required Medical Information	Pending CMS approval
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

REVLIMID

Products Affected

- Revlimid

PA Criteria	Criteria Details
Covered Uses	Pending CMS approval
Exclusion Criteria	Pregnancy
Required Medical Information	For active myeloma patient meets one of the following: 1) Revlimid is used in combination with dexamethasone. 2) Revlimid is used as maintenance monotherapy following response to either stem cell transplant or primary induction therapy. For mantle cell lymphoma (MCL): Revlimid is used after 2 prior therapies, 1 of which is bortezomib. For Low or Intermediate-1 Risk myelodysplastic syndrome (MDS): for those with 5q deletion, patients should have transfusion-dependent anemia or symptomatic anemia with clinically significant cytopenias. For those with non-5q deletion MDS and symptomatic anemia, patients should have failed to respond to epoetin alfa or darbepoetin or have a pretreatment serum erythropoietin levels greater than 500 mU/mL and a low probability of response to immunosuppressive therapy. For female patients of childbearing potential, pregnancy is excluded by 2 negative serum or urine pregnancy tests. For all patients, complete blood counts are monitored for hematologic toxicity while receiving Revlimid.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Male and female patients of child-bearing potential should be instructed on the importance of proper utilization of appropriate contraceptive methods for Revlimid use. Patients should be monitored for signs and symptoms of thromboembolism.



RIBA VIRIN

Products Affected

- ribavirin oral capsule
- ribavirin oral tablet 200 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Pending CMS approval
Required Medical Information	Prior to initiating therapy, detectable levels of HCV RNA in the serum. Must use in combination with Harvoni, interferon, Viekira, Daklinza, Technivie, Zepatier or Sovaldi. Cirrhosis documented by FibroScan, liver biopsy, or radiological imaging. genotype
Age Restrictions	N/A
Prescriber Restrictions	ID specialist, gastroenterologist, or oncologist
Coverage Duration	12 wks, 24 wks, or 48 wks as specified in Other Criteria.
Other Criteria	Pending CMS approval

RITUXAN

Products Affected

- Rituxan

PA Criteria	Criteria Details
Covered Uses	All medically-accepted indications not otherwise excluded from Part D. Patients already started on Rituxan for a Covered Use.
Exclusion Criteria	Concurrent use with a biologic agent (TNF alpha antagonists (eg, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), or anakinra, abatacept, tocilizumab or tofacitinib.
Required Medical Information	N/A
Age Restrictions	RA, adults.
Prescriber Restrictions	Adult with RA (initial course). Prescribed by a rheumatologist or in consultation with a rheumatologist.
Coverage Duration	Pending CMS approval
Other Criteria	Adult with RA (initial course), approve if Rituxan is prescribed in combination with methotrexate or another traditional DMARD (eg, leflunomide or sulfasalazine) unless the patient has been shown to be intolerant or has a contraindication to one or more traditional DMARDs AND the patient has tried one of certolizumab pegol, etanercept, adalimumab, infliximab, golimumab (ie, a TNF antagonist) OR if the patient has not yet tried a TNF antagonist, the patient must have a trial with etanercept or adalimumab.

SABRIL

Products Affected

- Sabril

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Patients with or at high risk of vision loss (except patients who have blindness). Patients using other medications associated with serious adverse ophthalmic effects such as retinopathy or glaucoma.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Infantile spasms: initial 4 wks, reauth 6 mths. CPS: initial 3 mths, reauth to plan year
Other Criteria	N/A



SAMSCA

Products Affected

- Samsca oral tablet 15 mg, 30 mg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Up to 30 days
Other Criteria	N/A



SANDOSTATIN LAR

Products Affected

- Sandostatin LAR Depot intramuscular suspension, extended rel recon

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Patient received initial treatment with Sandostatin Injection (not the Depot form) for at least 2 weeks and treatment with Sandostatin Injection was effective and tolerable.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

SIGNIFOR

Products Affected

- Signifor

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis for which Signifor is being used.
Age Restrictions	Cushing's, 18 years of age and older.
Prescriber Restrictions	Initial course, prescribed by or in consultation with an endocrinologist.
Coverage Duration	Initial therapy, approve for 3 months. Continuation therapy, approve for the plan year.
Other Criteria	Cushing's disease, approve if according to the prescribing physician the patient is not a candidate for surgery or surgery has not been curative. Patients who have already been started on Signifor for Cushing's disease will be approved if the patient has had a response, as determined by the prescribing physician and the patient is continuing therapy to maintain response.

SOVALDI

Products Affected

- Sovaldi

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	Concurrent treatment with Harvoni, Viekira, Technivie, Zepatier
Required Medical Information	Prior to initiating therapy, detectable levels of HCV RNA in the serum. Must be used in combination with interferon+ribavirin, ribavirin, Daklinza or Olysio. Cirrhosis documented by FibroScan, liver biopsy, or radiological imaging
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by or in consultation w/ GI, hepatologist, ID, or a liver transplant MD
Coverage Duration	12 wks, 24 wks, or 48 wks as specified in Other Criteria.
Other Criteria	Criteria will be applied consistent with current AASLD/IDSA guidance

SPRYCEL

Products Affected

- Sprycel oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Acute lymphoblastic leukemia (ALL) and newly diagnosed chronic myeloid leukemia (CML) must be positive for the Philadelphia chromosome or BCR-ABL gene. For CML, patient meets one of the following: 1) newly diagnosed in chronic phase, 2) resistance or intolerance to imatinib, or 3) relapse after stem cell transplant. For ALL, resistance or intolerance to prior therapy.
Age Restrictions	18 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

STIVARGA

Products Affected

- Stivarga

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D. Plus patients already started on Stivarga for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis for which Stivarga is being used. For metastatic colorectal cancer (CRC) and gastrointestinal stromal tumors (GIST), prior therapies tried. For metastatic CRC, KRAS mutation status.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For metastatic CRC with KRAS mutation, patient must have previously been treated with each of the following for approval: a fluoropyrimidine (eg, Xeloda, 5-FU), oxaliplatin, irinotecan, anti-VEGF therapy (eg, Avastin, Zaltrap). For metastatic CRC with no detected KRAS mutations (ie, KRAS wild-type), patient must have previously been treated with each of the following for approval: a fluoropyrimidine (eg, Xeloda, 5-FU), oxaliplatin, irinotecan, anti-VEGF therapy (eg, Avastin, Zaltrap), anti-EGFR therapy (eg, Eribitux, Vectibix). For GIST, patient must have previously been treated with imatinib (Gleevec) and sunitinib (Sutent).

SUTENT

Products Affected

- Sutent

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Clinical manifestations of congestive heart failure.
Required Medical Information	For gastrointestinal stromal tumor (GIST), disease progression while on an at least 30-day regimen of Gleevec or intolerance to Gleevec is required. LFT monitoring at initiation of therapy and throughout treatment.
Age Restrictions	N/A
Prescriber Restrictions	Oncologist
Coverage Duration	Plan Year
Other Criteria	Therapy will be interrupted for serious hepatic adverse events and discontinued if serious hepatic adverse events do not resolve.



SYLATRON

Products Affected

- Sylatron

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

SYNAGIS

Products Affected

- Synagis intramuscular solution 50 mg/0.5 mL

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	<p>Prophylaxis of Respiratory Syncytial Virus (RSV): One of the following: (criteria 1) all of the following: Infant is less than 24 months of age, infant has chronic lung disease (CLD), infant required medical therapy (supplemental oxygen, bronchodilator, diuretic or corticosteroid therapy) within 6 months prior to the start of RSV season, (criteria 2) all of the following: infant was born at 28 weeks of gestation or earlier, infant does not have chronic lung disease (CLD), and infant was less than 12 months of age at the start of RSV season, (criteria 3) all of the following: infant was born at 29 to 32 weeks of gestation (ie, 31 weeks, 6 days or less), infant does not have chronic lung disease (CLD), and infant was less than 6 months of age at the start of RSV season. (criteria 4): infant was born at 32 to less than 35 weeks of gestation (ie, between 32 weeks, 0 days through 34 weeks, 6 days), infant does not have CLD, infant was less than 3 months of age at the start of the RSV season, and infant has one of the following risk factors: (1) Child care attendance defined as a home or facility in which care is provided for any number of infants or toddlers OR (2) Infant has a sibling younger than 5 years of age, (criteria 5) both of the following: Infants and children 24 months of age and younger, or Infant or child has one of the following: (1) Congenital abnormalities of the airways, or (2) Neuromuscular condition that compromises handling of respiratory secretions, (criteria 6) both of the following: Infants and children 24 months of age or younger, or infant or child has hemodynamically significant cyanotic or acyanotic congenital heart disease (CHD) (eg, receiving medication to control congestive heart failure, moderate to severe pulmonary hypertension), (criteria 7) both of the following: Infants and children 24 months of age and younger, infant or child has severe immunodeficiency (eg, severe combined immunodeficiency or advanced AIDS) (off label).</p>
Age Restrictions	N/A
Prescriber Restrictions	N/A

PA Criteria	Criteria Details
Coverage Duration	5 months
Other Criteria	Synagis will not be approved for the following conditions unless one of the required criteria is met: 1) Infants and children with hemodynamically insignificant heart disease (eg, secundum atrial septal defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus), 2) Infants with lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure, 3) Infants with mild cardiomyopathy who are not receiving medical therapy for the condition.



TAFINLAR

Products Affected

- Tafinlar

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Documentation of the detected BRAF V600E or V600K mutations
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

TAGRISSO

Products Affected

- Tagrisso

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus patients already started on Tagrisso for a covered use.
Exclusion Criteria	EGFR tyrosine kinase inhibitor treatment naive patients
Required Medical Information	Confirmed T790M mutation-positive NSCLC as detected by an FDA approved test and Prior therapies tried
Age Restrictions	18 years or older
Prescriber Restrictions	Prescribed by, or in consultation with, an Oncologist
Coverage Duration	Plan Year
Other Criteria	The patient has metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC as detected by an FDA approved test AND The patient has progressed on or after one of Tarceva (erlotinib tablets), Iressa (gefitinib tablets), or Gilotrif (afatinib tablets) therapy.



TARCEVA

Products Affected

- Tarceva oral tablet 100 mg, 150 mg, 25 mg

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	For 1st line therapy of locally advanced or metastatic NSCLC, patient should have a known active EGFR exon 19 deletions or exon 21 substitution mutation or amplification of the EGFR gene.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

TARGRETIN

Products Affected

- bexarotene

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D
Exclusion Criteria	Pregnancy
Required Medical Information	For capsules, patient meets one of the following: 1) cutaneous T cell lymphoma (includes mycosis fungoides [MF] and Sezary syndrome [SS]) refractory to prior systemic therapy, 2) advanced-stage MF/Sezary syndrome, 3) early-stage MF refractory/progressive to skin-directed therapy, or 4) early-stage MF with blood involvement or folliculotropic/large cell transformation.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Patient has been instructed on the importance of and proper utilization of contraception.

TASIGNA

Products Affected

- Tasigna

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Long QT syndrome, uncorrected electrolyte disorders (hypokalemia, hypomagnesemia).
Required Medical Information	ECG obtained at baseline, 7-10 days after initiation of therapy and periodically throughout therapy. Newly diagnosed chronic myeloid leukemia (CML) must be positive for the Philadelphia chromosome or BCR-ABL gene. For CML, patient meets one of the following: 1) newly diagnosed in chronic phase, 2) resistance to imatinib, 3) intolerance/toxicity to imatinib or dasatinib, or 4) relapse after stem cell transplant.
Age Restrictions	18 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Patient has been instructed to avoid eating food 2 hours before and 1 hour after taking Tasigna. Concomitant use of drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided.



TECENTRIQ

Products Affected

- Tecentriq

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan year
Other Criteria	N/A

TETRABENAZINE

Products Affected

- tetrabenazine

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Tardive dyskinesia (TD). Tourette syndrome and related tic disorders. Hyperkinetic dystonia. Hemiballism.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	For treatment of chorea associated with Huntington's disease, Tourette syndrome or related tic disorders, hyperkinetic dystonia, or hemiballism, must be prescribed by or after consultation with a neurologist. For TD, must be prescribed by or after consultation with a neurologist or psychiatrist.
Coverage Duration	Plan Year
Other Criteria	N/A

THALOMID

Products Affected

- Thalomid

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Pregnancy
Required Medical Information	For active myeloma, patient meets one of the following: 1) Thalomid is used as salvage or palliative therapy. 2) Thalomid is used for newly diagnosed disease or as primary induction therapy in combination with dexamethasone or in combination with melphalan and prednisone in nontransplant candidates. 3) Thalomid is used as maintenance monotherapy following response to either stem cell transplant or primary induction therapy. For female patients of childbearing potential, pregnancy is excluded by a negative pregnancy test.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Patients are monitored for signs and symptoms of thromboembolism. Male and female patients of child-bearing potential are instructed on the importance of proper utilization of appropriate contraceptive methods.



THIORIDAZINE

Products Affected

- thioridazine

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A



THIOTEPA

Products Affected

- thiotepa

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

TIRF MEDICATIONS

Products Affected

- fentanyl citrate buccal lozenge on a handle
1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For breakthrough pain in patients with cancer if patient is unable to swallow, has dysphagia, esophagitis, mucositis, or uncontrollable nausea/vomiting OR patient is unable to take 2 other short-acting narcotics (eg, oxycodone, morphine sulfate, hydromorphone, etc) secondary to allergy or severe adverse events AND patient is on or will be on a long-acting narcotic (eg, Duragesic), or the patient is on intravenous, subcutaneous, or spinal (intrathecal, epidural) narcotics (eg, morphine sulfate, hydromorphone, fentanyl citrate).

TRETINOIN

Products Affected

- adapalene topical cream
- adapalene topical gel
- tretinoin microspheres topical gel with pump
- tretinoin topical

PA Criteria	Criteria Details
Covered Uses	All medically accepted indications not otherwise excluded from Part D.
Exclusion Criteria	Coverage is not provided for cosmetic use.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

TYKERB

Products Affected

- Tykerb

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Liver function tests must be monitored at baseline and every four to six weeks during therapy and as clinically indicated. In patients with severe hepatic impairment, Tykerb is used at a reduced dose.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

TYSABRI

Products Affected

- Tysabri

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D. Plus patients already started on Tysabri for a Covered Use.
Exclusion Criteria	Concurrent use of another immunomodulator (eg, Rebif, Betaseron, Extavia, Copaxone or Avonex or Aubagio), Tecfidera, or fingolimod (Gilenya) or an immunosuppressant such as mitoxantrone, cyclophosphamide, rituximab (Rituxan), alemtuzumab (Campath), azathioprine, MTX, or mycophenolate mofetil in multiple sclerosis (MS) patients. Concurrent use with immunosuppressants (eg, 6-mercaptopurine, azathioprine, cyclosporine, methotrexate) or tumor necrosis factor (TNF) alfa inhibitors (eg, infliximab, adalimumab, certolizumab pegol) in Crohn's disease (CD) patients. Per warning and precautions, coverage is not provided for immune compromised patients with MS or CD.
Required Medical Information	Adults with MS. Patient has a relapsing form of MS (relapsing forms of MS are relapsing remitting [RRMS], secondary progressive [SPMS] with relapses, and progressive relapsing [PRMS]). Adults with CD. Patient has moderately to severely active CD with evidence of inflammation (eg, elevated C-reactive protein).
Age Restrictions	Adults
Prescriber Restrictions	MS. Prescribed by, or in consultation with , a neurologist or physician who specializes in the treatment of MS.CD. Prescribed by or in consultation with a gastroenterologist.
Coverage Duration	Plan Year

PA Criteria	Criteria Details
Other Criteria	<p>Adults with a relapsing form of MS. Patient has had an inadequate response to, or is unable to tolerate, therapy with at least one of the following MS medications: interferon beta-1a (Avonex, Rebif), interferon beta-1b (Betaseron, Extavia), glatiramer acetate (Copaxone), fingolimod (Gilenya), Tecfidera, or Aubagio OR the patient has highly active or aggressive disease according to the prescribing physician. Adults with CD. Patient has moderately to severely active CD with evidence of inflammation (eg, elevated C-reactive protein) and patient has tried two TNF antagonists for CD for at least 2 months each, adalimumab, certolizumab pegol, or infliximab, and had an inadequate response or was intolerant to the TNF antagonists.</p>



TYVASO

Products Affected

- Tyvaso

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	PAH been confirmed by right heart catheterization.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Part B versus D determination per CMS guidance.

UPTRAVI

Products Affected

- Uptravi oral tablet

- Uptravi oral tablets,dose pack

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Breast feeding mother, severe hepatic impairment (Child-Pugh Class C)
Required Medical Information	prior treatments
Age Restrictions	18 years of age or older
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Must have PAH (WHO Group 1) and had a right heart catheterization to confirm the diagnosis of PAH (WHO Group 1). Right heart catheterization is NOT required in pts who are currently receiving Uptravi or another agent indicated for PAH (WHO group 1). Patient must have previously tried or is currently taking at least one other agent indicated for PAH treatment (eg, sildenafil, Adcirca, Revatio, Tracleer, Letairis Opsumit, Adempas, Orenitram, Tyvaso, Ventavis, Remodulin, or epoprostenol injection).



VENCLEXTA

Products Affected

- Venclexta

- Venclexta Starting Pack

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Diagnosis, prior therapy, 17p deletion status
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	CLL - approve if the patient has 17p deletion and has tried one prior therapy.

VIMPAT

Products Affected

- Vimpat intravenous
- Vimpat oral solution
- Vimpat oral tablet

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Pending CMS approval
Age Restrictions	17 years of age and older
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

VOTRIENT

Products Affected

- Votrient

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	Alanine transaminase (ALT) greater than 3 times the upper limit of normal (ULN) and bilirubin greater than 2 times the ULN.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	Oncologist
Coverage Duration	Plan Year
Other Criteria	N/A

XALKORI

Products Affected

- Xalkori

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus, patients with non-small cell lung cancer (NSCLC) already started on crizotinib.
Exclusion Criteria	N/A
Required Medical Information	For the FDA-approved indication of NSCLC for patients new to therapy, ALK status required. ROS1 Status
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	NSCLC, patient new to therapy must be ALK-positive for approval.

XOLAIR

Products Affected

- Xolair

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	For IgE-mediated allergic asthma: pre-treatment serum IgE level greater than or equal to 30 IU/mL to less than or equal to 700 IU/mL and patient's weight
Age Restrictions	Pending CMS approval
Prescriber Restrictions	Pending CMS approval
Coverage Duration	Plan Year
Other Criteria	To continue therapy, patients must demonstrate an improvement in asthma control with use of Xolair.

XTANDI

Products Affected

- Xtandi

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D. Plus patients already started on Xtandi for a Covered Use.
Exclusion Criteria	N/A
Required Medical Information	Diagnosis for which Xtandi is being used. For metastatic castration-resistant prostate cancer, prior therapies tried.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For prostate cancer, patient must have metastatic, castration-resistant prostate cancer for approval. Patient must have tried or be intolerant to Zytiga.

YERVOY

Products Affected

- Yervoy intravenous solution 50 mg/10 mL (5 mg/mL)

PA Criteria	Criteria Details
Covered Uses	All FDA approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ZALTRAP

Products Affected

- Zaltrap intravenous solution 100 mg/4 mL (25 mg/mL)

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D.
Exclusion Criteria	N/A
Required Medical Information	Prior therapies tried.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For metastatic colorectal cancer, must be used in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI).

ZELBORAF

Products Affected

- Zelboraf

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D. Plus, patients with melanoma already started on vemurafenib.
Exclusion Criteria	N/A
Required Medical Information	For the FDA-approved indication of melanoma, for patients new to therapy, BRAFV600E status required.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	Melanoma, patient new to therapy must have BRAFV600E mutation for approval.



ZOLEDRONIC ACID

Products Affected

- zoledronic acid-mannitol-water intravenous solution

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D and patients already started on zoledronic acid for a covered use.
Exclusion Criteria	Concurrent Use with Other Medications for Osteoporosis (e.g., other bisphosphonates, Prolia, Forteo, Evista, calcitonin nasal spray), except calcium and Vitamin D.
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Paget's 1 month. Others 12 months.

PA Criteria	Criteria Details
<p>Other Criteria</p>	<p>Treatment of osteoporosis in post menopausal women or osteoporosis in men, must meet ONE of the following patient had an inadequate response after a trial duration of 12 months (eg, ongoing and significant loss of BMD, lack of BMD increase) or patient had an osteoporotic fracture while receiving therapy or patient experienced intolerability (eg, severe GI-related adverse effects, severe musculoskeletal-related side effects, a femoral fracture), OR pt cannot take an oral bisphosphonate because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphosphonate administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]). Prevention or treatment of glucocorticoid induced osteoporosis (GIO), approve if: pt is initiating or continuing therapy with systemic glucocorticoids, AND has had an inadequate response after a trial duration of 12 months (eg, ongoing and significant loss of BMD, lack of BMD increase) or patient had an osteoporotic fracture while receiving therapy or patient experienced intolerability (eg, severe GI-related adverse effects, severe musculoskeletal-related side effects, a femoral fracture), OR pt cannot take an oral bisphosphonate because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphosphonate administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]). Treatment of Paget's disease, approve if patient has elevations in serum alkaline phosphatase of two times higher than the upper limit of the age-specific normal reference range, OR patient is symptomatic (eg, bone pain, hearing loss, osteoarthritis), OR patient is at risk for complications from their disease (eg, immobilization, bone deformity, fractures, nerve compression syndrome). Preventions of PMO - meets one of the following had an inadequate response after a trial duration of 12 months (eg, ongoing and significant loss of BMD, lack of BMD increase) or patient had an osteoporotic fracture while receiving therapy or patient experienced intolerability (eg, severe GI-related adverse effects, severe musculoskeletal-related side effects, a femoral fracture), OR pt cannot take an oral bisphosphonate because the pt cannot swallow or has difficulty swallowing or the pt cannot remain in an upright position post oral bisphosphonate administration or pt has a pre-existing GI medical condition (eg, patient with esophageal lesions, esophageal ulcers, or abnormalities of the esophagus that delay esophageal emptying [stricture, achalasia]). Part B versus Part D determination will be made at time of prior authorization review per CMS guidance.</p>

ZYDELIG

Products Affected

- Zydelig

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	Documentation of AST/ALT less than 20 x ULN and Bilirubin less than 10 x ULN.
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	N/A

ZYKADIA

Products Affected

- Zykadia

PA Criteria	Criteria Details
Covered Uses	All FDA-approved indications not otherwise excluded from Part D
Exclusion Criteria	N/A
Required Medical Information	N/A
Age Restrictions	N/A
Prescriber Restrictions	N/A
Coverage Duration	Plan Year
Other Criteria	For metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive, patient must have progressed or be intolerant to crizotinib for approval.

PART B VERSUS PART D

Products Affected

- Abelcet
- Abilify Maintena intramuscular suspension, extended rel recon 300 mg
- Abraxane
- acetylcysteine
- Actemra intravenous
- acyclovir sodium intravenous solution
- Adagen
- Adrucil intravenous solution 500 mg/10 mL
- A-Hydrocort
- albuterol sulfate inhalation solution for nebulization 0.63 mg/3 mL, 1.25 mg/3 mL, 2.5 mg /3 mL (0.083 %), 5 mg/mL
- Aldurazyme
- Alimta intravenous recon soln 500 mg
- AmBisome
- amifostine crystalline
- amikacin injection solution 500 mg/2 mL
- amino acids 15 %
- Aminosyn 8.5 %-electrolytes
- Aminosyn II 10 %
- Aminosyn II 15 %
- Aminosyn II 7 %
- Aminosyn II 8.5 %
- Aminosyn II 8.5 %-electrolytes
- Aminosyn-HBC 7%
- Aminosyn-PF 10 %
- Aminosyn-PF 7 % (sulfite-free)
- Aminosyn-RF 5.2 %
- amiodarone intravenous solution
- amphotericin B
- ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg
- ampicillin-sulbactam injection recon soln 15 gram, 3 gram
- Aralast NP intravenous recon soln 500 mg
- Astagraf XL
- Avastin
- Avelox in NaCl (iso-osmotic)
- Azasan
- azathioprine
- azathioprine sodium
- azithromycin intravenous
- BACiiM
- BCG vaccine, live (PF)
- Beleodaq
- Benlysta
- benztropine injection
- BiCNU
- bleomycin injection recon soln 30 unit
- budesonide inhalation suspension for nebulization 0.25 mg/2 mL, 0.5 mg/2 mL, 1 mg/2 mL
- buprenorphine HCl injection
- Busulfex
- calcitriol intravenous solution 1 mcg/mL
- calcitriol oral
- Cancidas
- Capastat
- carboplatin intravenous solution
- cefazolin injection recon soln 1 gram, 10 gram, 500 mg
- cefepime
- cefoxitin
- ceftriaxone injection recon soln 250 mg, 500 mg
- ceftriaxone intravenous recon soln 2 gram
- cefuroxime sodium injection recon soln 1.5 gram, 750 mg
- cefuroxime sodium intravenous
- CellCept Intravenous
- CellCept oral suspension for reconstitution
- Cerezyme intravenous recon soln 400 unit
- chloramphenicol sod succinate
- cidofovir
- Cimzia Powder for Reconst
- ciprofloxacin lactate intravenous solution 400 mg/40 mL
- cisplatin
- cladribine
- clindamycin phosphate injection
- clindamycin phosphate intravenous solution 600 mg/4 mL

- Clinimix 5%/D15W Sulfite Free
- Clinimix 5%/D25W sulfite-free
- Clinimix 2.75%/D5W Sulfit Free
- Clinimix 4.25%/D10W Sulf Free
- Clinimix 4.25%/D5W Sulfit Free
- Clinimix 4.25%-D20W sulf-free
- Clinimix 4.25%-D25W sulf-free
- Clinimix 5%-D20W(sulfite-free)
- Clinimix E 2.75%/D10W Sul Free
- Clinimix E 2.75%/D5W Sulf Free
- Clinimix E 4.25%/D10W Sul Free
- Clinimix E 4.25%/D25W Sul Free
- Clinimix E 4.25%/D5W Sulf Free
- Clinimix E 5%/D15W Sulfit Free
- Clinimix E 5%/D20W Sulfit Free
- Clinimix E 5%/D25W Sulfit Free
- colistin (colistimethate Na)
- cromolyn inhalation
- cyclophosphamide oral capsule
- cyclosporine intravenous
- cyclosporine modified
- cyclosporine oral capsule
- cytarabine
- D2.5 %-0.45 % sodium chloride
- D5 % and 0.9 % sodium chloride
- D5 %-0.45 % sodium chloride
- dacarbazine intravenous recon soln 200 mg
- daunorubicin intravenous solution
- decitabine
- Depo-Provera intramuscular solution
- dexamethasone sodium phosphate injection solution
- dexrazoxane HCl intravenous recon soln 250 mg
- dextrose 10 % and 0.2 % NaCl
- dextrose 10 % in water (D10W)
- dextrose 5 % in water (D5W) intravenous parenteral solution
- dextrose 5 %-lactated ringers
- dextrose 5%-0.2 % sod chloride
- dextrose 5%-0.3 % sod.chloride
- Dextrose With Sodium Chloride
- Dextrose-KCl-NaCl
- diltiazem HCl intravenous
- diphenhydramine HCl injection solution 50 mg/mL
- doxorubicin intravenous solution 50 mg/25 mL
- doxorubicin, peg-liposomal
- doxycycline hyclate intravenous
- dronabinol
- Duramorph (PF) injection solution 0.5 mg/mL, 1 mg/mL
- Elaprase
- Elelyso
- Elitek
- Engerix-B (PF) intramuscular syringe
- Engerix-B Pediatric (PF)
- Envarsus XR
- Erythrocin intravenous recon soln 500 mg
- esomeprazole sodium
- etoposide intravenous
- famotidine (PF)
- famotidine (PF)-NaCl (iso-os)
- Faslodex
- fluconazole in NaCl (iso-osm) intravenous piggyback 200 mg/100 mL, 400 mg/200 mL
- fludarabine intravenous recon soln
- fluorouracil intravenous solution 2.5 gram/50 mL
- fluphenazine decanoate
- fluphenazine HCl injection
- fomepizole
- fosphenytoin injection solution 100 mg PE/2 mL
- furosemide injection
- ganciclovir sodium
- gemcitabine intravenous recon soln 1 gram
- Gengraf oral capsule 100 mg, 25 mg
- Gengraf oral solution
- gentamicin injection solution 40 mg/mL
- Geodon intramuscular
- granisetron (PF) intravenous solution 100 mcg/mL
- granisetron HCl
- haloperidol decanoate
- haloperidol lactate injection

- heparin (porcine) in 5 % dex intravenous parenteral solution 20,000 unit/500 mL (40 unit/mL), 25,000 unit/250 mL(100 unit/mL), 25,000 unit/500 mL (50 unit/mL)
- heparin (porcine) injection solution
- Hepatamine 8%
- Herceptin
- hydralazine injection
- hydromorphone (PF) injection solution 10 (mg/mL) (5 ml), 10 mg/mL
- hydroxyzine HCl intramuscular
- idarubicin
- ifosfamide intravenous recon soln 1 gram
- imipenem-cilastatin
- Increlex
- Intralipid intravenous emulsion 20 %, 30 %
- Intron A injection recon soln
- Intron A injection solution 6 million unit/mL
- Invanz injection
- ipratropium bromide inhalation
- ipratropium-albuterol
- irinotecan intravenous solution 100 mg/5 mL
- Istodax
- labetalol intravenous solution
- leucovorin calcium injection recon soln 100 mg, 350 mg
- levalbuterol HCl inhalation solution for nebulization 0.31 mg/3 mL, 0.63 mg/3 mL, 1.25 mg/0.5 mL
- levetiracetam intravenous
- levocarnitine (with sugar)
- levocarnitine oral tablet
- levofloxacin intravenous
- levoleucovorin calcium
- lidocaine (PF) injection solution 5 mg/mL (0.5 %)
- lidocaine HCl injection solution 20 mg/mL (2 %)
- magnesium sulfate injection
- melphalan HCl
- meropenem intravenous recon soln 500 mg
- mesna
- methadone injection
- methotrexate sodium (PF)
- methotrexate sodium oral
- methylprednisolone acetate
- methylprednisolone sodium succ injection recon soln 125 mg, 40 mg
- metoclopramide HCl injection solution
- metoprolol tartrate intravenous
- Miacalcin injection
- mitomycin
- mitoxantrone
- morphine intravenous syringe 10 mg/mL, 8 mg/mL
- Mozobil
- Mustargen
- mycophenolate mofetil
- mycophenolate sodium
- nafcillin injection recon soln 1 gram, 10 gram
- Naglazyme
- nalbuphine injection solution 10 mg/mL, 20 mg/mL
- Nebupent
- Neoral
- Nephramine 5.4 %
- nitroglycerin intravenous
- Normosol-M in 5 % dextrose
- Normosol-R in 5 % dextrose
- Normosol-R pH 7.4
- Nulojix
- ondansetron
- ondansetron HCl (PF)
- ondansetron HCl oral
- oxaliplatin intravenous solution 100 mg/20 mL
- paclitaxel
- pamidronate intravenous solution
- paricalcitol oral
- penicillin G potassium injection recon soln 5 million unit
- penicillin G sodium
- Pentam
- Perforomist
- phenytoin sodium intravenous solution
- piperacillin-tazobactam intravenous recon soln 3.375 gram, 4.5 gram, 40.5 gram
- Plasma-Lyte 148
- Plasma-Lyte A

- Plasma-Lyte-56 in 5 % dextrose
- potassium chlorid-D5-0.45%NaCl
- potassium chloride in 0.9%NaCl intravenous parenteral solution 20 mEq/L, 40 mEq/L
- potassium chloride in 5 % dex intravenous parenteral solution 20 mEq/L, 40 mEq/L
- potassium chloride in LR-D5 intravenous parenteral solution 20 mEq/L
- potassium chloride-D5-0.2%NaCl intravenous parenteral solution 20 mEq/L
- potassium chloride-D5-0.3%NaCl intravenous parenteral solution 20 mEq/L
- potassium chloride-D5-0.9%NaCl
- Premarin injection
- Premasol 10 %
- Premasol 6 %
- Procalamine 3%
- Proleukin
- propranolol intravenous
- Prosol 20 %
- Pulmozyme
- ranitidine HCl injection solution 25 mg/mL
- Rapamune
- Recombivax HB (PF) intramuscular suspension 10 mcg/mL, 40 mcg/mL
- Recombivax HB (PF) intramuscular syringe
- Remodulin
- rifampin intravenous
- ringers intravenous
- Risperdal Consta
- Sancuso
- Sandimmune oral
- Simulect intravenous recon soln 20 mg
- sirolimus
- Solu-Cortef (PF) injection recon soln 100 mg/2 mL, 250 mg/2 mL
- Somatuline Depot
- Somavert
- streptomycin intramuscular
- sulfamethoxazole-trimethoprim intravenous
- Synercid
- Synribo
- tacrolimus oral
- Teflaro
- testosterone cypionate
- testosterone enanthate
- tetanus-diphtheria toxoids-Td
- tobramycin in 0.225 % NaCl
- tobramycin sulfate injection solution
- Toposar
- topotecan intravenous recon soln
- tranexamic acid intravenous
- Travasol 10 %
- Treanda intravenous recon soln 100 mg
- Trelstar intramuscular suspension for reconstitution
- Trelstar intramuscular syringe 11.25 mg/2 mL, 3.75 mg/2 mL
- Trisenox
- TrophAmine 10 %
- Trophamine 6%
- Twinrix (PF) intramuscular suspension
- valproate sodium
- vancomycin intravenous recon soln 1,000 mg, 10 gram, 500 mg
- Varubi
- Velcade
- verapamil intravenous solution
- vinblastine intravenous solution
- Vincasar PFS intravenous solution 1 mg/mL
- vincristine intravenous solution 1 mg/mL
- vinorelbine intravenous solution 50 mg/5 mL
- Virazole
- voriconazole intravenous
- VPRIV
- Xgeva
- Zemplar intravenous
- zoledronic acid intravenous solution
- Zometa intravenous solution 4 mg/100 mL
- Zortress
- Zyprexa Relprevv intramuscular suspension for reconstitution 210 mg

Details



This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

Index

A

Abelcet	168
Abilify Maintena.....	168
Abraxane	168
acetylcysteine.....	168
Actemra.....	168
Acthar H.P.....	1
Actimmune.....	2
acyclovir sodium.....	168
Adagen	168
adapalene topical cream.....	149
adapalene topical gel.....	149
Adcirca.....	3
Adempas	4
Adrucil	168
Afinitor.....	5
Afinitor Disperz	5
A-Hydrocort.....	168
albuterol sulfate.....	168
Aldurazyme.....	168
Alecensa.....	6
Alimta	168
alosetron.....	7
alprazolam oral tablet extended release 24 hr	53
AmBisome	168
amifostine crystalline.....	168
amikacin.....	168
amino acids 15 %	168
Aminosyn 8.5 %-electrolytes.....	168
Aminosyn II 10 %	168
Aminosyn II 15 %	168
Aminosyn II 7 %	168
Aminosyn II 8.5 %	168
Aminosyn II 8.5 %-electrolytes	168
Aminosyn-HBC 7%	168
Aminosyn-PF 10 %	168
Aminosyn-PF 7 % (sulfite-free).....	168
Aminosyn-RF 5.2 %	168
amiodarone.....	168
amitriptyline.....	55
amphotericin B.....	168
ampicillin sodium.....	168
ampicillin-sulbactam.....	168

Ampyra	8
Anadrol-50	9
APOKYN.....	11
Aptiom	12
Aralast NP.....	168
Arcalyst.....	13
Astagraf XL	168
Aubagio.....	14
Avastin	168
Avelox in NaCl (iso-osmotic).....	168
Avonex (with albumin).....	15
Avonex intramuscular pen injector kit.....	15
Avonex intramuscular syringe kit.....	15
Azasan.....	168
azathioprine.....	168
azathioprine sodium.....	168
azithromycin	168

B

BACiiM.....	168
Banzel oral tablet	16
BCG vaccine, live (PF).....	168
Beleodaq	168
Benlysta.....	168
benztropine.....	168
benztropine oral	52
bexarotene.....	141
BiCNU	168
bleomycin.....	168
Bosulif.....	17
Briviact.....	18
budesonide	168
buprenorphine HCl.....	168
Busulfex	168
butalbital-acetaminop-caf-cod	52
butalbital-acetaminophen.....	52
butalbital-acetaminophen-caff oral capsule	52
butalbital-acetaminophen-caff oral tablet 50- 325-40 mg	52
butalbital-aspirin-caffeine oral capsule.....	52

C

Cabometyx	19
calcitriol	168
Candidas.....	168

Capastat.....	168	Crinone.....	27
Carbaglu.....	20	cromolyn.....	169
carboplatin.....	168	cyclobenzaprine oral tablet.....	52
cefazolin.....	168	cyclophosphamide.....	169
cefepime.....	168	cyclosporine.....	169
cefoxitin.....	168	cyclosporine modified.....	169
ceftriaxone.....	168	cyproheptadine.....	52
cefuroxime sodium.....	168	Cyramza.....	28
CellCept.....	168	cytarabine.....	169
CellCept Intravenous.....	168	D	
Cerezyme.....	168	D2.5 %-0.45 % sodium chloride.....	169
chloramphenicol sod succinate.....	168	D5 % and 0.9 % sodium chloride.....	169
Cholbam.....	21	D5 %-0.45 % sodium chloride.....	169
chorionic gonadotropin, human.....	22	dacarbazine.....	169
Cialis oral tablet 2.5 mg, 5 mg.....	23	Daraprim.....	29
cidofovir.....	168	Darzalex.....	30
Cimzia Powder for Reconst.....	168	daunorubicin.....	169
Cinryze.....	24	decitabine.....	169
ciprofloxacin lactate.....	168	Demser.....	31
cisplatin.....	168	Depen Titratabs.....	104
cladribine.....	168	Depo-Provera.....	169
clemastine oral tablet 2.68 mg.....	52	dexamethasone sodium phosphate.....	169
clindamycin phosphate.....	168	dextrazoxane HCl.....	169
Clinimix 5%/D15W Sulfite Free.....	169	dextrose 10 % and 0.2 % NaCl.....	169
Clinimix 5%/D25W sulfite-free.....	169	dextrose 10 % in water (D10W).....	169
Clinimix 2.75%/D5W Sulfit Free.....	169	dextrose 5 % in water (D5W).....	169
Clinimix 4.25%/D10W Sulf Free.....	169	dextrose 5 %-lactated ringers.....	169
Clinimix 4.25%/D5W Sulfit Free.....	169	dextrose 5%-0.2 % sod chloride.....	169
Clinimix 4.25%-D20W sulf-free.....	169	dextrose 5%-0.3 % sod.chloride.....	169
Clinimix 4.25%-D25W sulf-free.....	169	Dextrose With Sodium Chloride.....	169
Clinimix 5%-D20W(sulfite-free).....	169	Dextrose-KCl-NaCl.....	169
Clinimix E 2.75%/D10W Sul Free.....	169	Diastat.....	54
Clinimix E 2.75%/D5W Sulf Free.....	169	Diazepam Intensol.....	54
Clinimix E 4.25%/D10W Sul Free.....	169	diazepam oral solution 5 mg/5 mL (1 mg/mL).....	54
Clinimix E 4.25%/D25W Sul Free.....	169	diazepam oral tablet.....	54
Clinimix E 4.25%/D5W Sulf Free.....	169	diazepam rectal.....	54
Clinimix E 5%/D15W Sulfit Free.....	169	diclofenac sodium topical gel 3 %.....	32
Clinimix E 5%/D20W Sulfit Free.....	169	Digitek.....	33
Clinimix E 5%/D25W Sulfit Free.....	169	digoxin injection solution.....	33
clomipramine.....	55	digoxin oral solution 50 mcg/mL.....	33
clonazepam oral tablet,disintegrating.....	54	digoxin oral tablet.....	33
clorazepate dipotassium.....	54	diltiazem HCl.....	169
colistin (colistimethate Na).....	169	diphenhydramine HCl.....	169
Cometriq.....	25	doxepin oral.....	55
Copaxone subcutaneous syringe.....	48	doxorubicin.....	169
Cotellic.....	26		

doxorubicin, peg-liposomal	169
doxycycline hyclate	169
dronabinol	169
Duramorph (PF)	169

E

Egrifta subcutaneous recon soln 1 mg	34
Elaprase	169
Elelyso	169
Eligard	78
Elitek	169
Empliciti	35
Engerix-B (PF)	169
Engerix-B Pediatric (PF)	169
Entresto	36
Envarsus XR	169
ergoloid	52
Erivedge	37
Erwinaze	38
Erythrocine	169
Esbriet	39
esomeprazole sodium	169
estradiol oral	55
etoposide	169
Extavia subcutaneous kit	40

F

Fabrazyme intravenous recon soln 35 mg	41
famotidine (PF)	169
famotidine (PF)-NaCl (iso-os)	169
Farydak	42
Faslodex	169
fentanyl citrate buccal lozenge on a handle 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg	148
Ferriprox oral tablet	43
Firazyr	44
fluconazole in NaCl (iso-osm)	169
fludarabine	169
fluorouracil	169
fluphenazine decanoate	169
fluphenazine HCl	169
fomepizole	169
fosphenytoin	169
furosemide	169
Fycompa oral suspension	45
Fycompa oral tablet	45

G

Gammagard Liquid	64
Gamunex-C injection solution 1 gram/10 mL (10 %)	64
ganciclovir sodium	169
Gattex One-Vial	46
gemcitabine	169
Gengraf	169
gentamicin	169
Geodon	169
Gilotrif	47
Glatopa	48
Gleevec oral tablet 100 mg, 400 mg	60
granisetron (PF)	169
granisetron HCl	169

H

haloperidol decanoate	169
haloperidol lactate	169
Harvoni	50
heparin (porcine)	170
heparin (porcine) in 5 % dex	170
Hepatamine 8%	170
Herceptin	170
Hetlioz	51
hydralazine	170
hydromorphone (PF)	170
hydroxyprogesterone caproate	56
hydroxyzine HCl	170

I

Ibrance	57
Iclusig	58
idarubicin	170
ifosfamide	170
Ilaris (PF)	59
imatinib oral tablet 100 mg, 400 mg	60
Imbruvica	61
imipenem-cilastatin	170
imipramine HCl	55
imipramine pamoate	55
Increlex	170
Inlyta	62
Intralipid	170
Intron A	170
Invanz	170
ipratropium bromide	170
ipratropium-albuterol	170

Iressa	63	megestrol oral tablet.....	55
irinotecan.....	170	Mekinist	84
Istodax.....	170	melphalan HCl	170
J		memantine.....	86
Jakafi oral tablet 10 mg, 15 mg, 20 mg, 25 mg, 5 mg	65	meprobamate.....	52
Juxtapid.....	66	meropenem.....	170
K		mesna	170
Kadcyla intravenous recon soln 100 mg ...	67	metaxalone	52
Kalydeco	68	methadone	170
Keveyis	69	methamphetamine	85
Keytruda.....	71	methotrexate sodium.....	170
Korlym	72	methotrexate sodium (PF).....	170
Kuvan oral tablet,soluble	73	methyldopa-hydrochlorothiazide	52
Kynamro	74	methylprednisolone acetate.....	170
L		methylprednisolone sodium succ.....	170
labetalol.....	170	metoclopramide HCl.....	170
Lenvima	75	metoprolol tartrate.....	170
Letairis	76	Miacalcin.....	170
leucovorin calcium.....	170	mitomycin	170
Leukine injection recon soln.....	77	mitoxantrone	170
levabuterol HCl.....	170	modafinil	94
levetiracetam	170	morphine	170
levocarnitine.....	170	Mozobil	170
levocarnitine (with sugar)	170	Mustargen	170
levofloxacin.....	170	mycophenolate mofetil.....	170
levoleucovorin calcium.....	170	mycophenolate sodium	170
lidocaine (PF).....	170	N	
lidocaine HCl	170	nafeillin	170
lidocaine topical adhesive patch,medicated	79	Naglazyme	170
linezolid.....	80	nalbuphine.....	170
Lonsurf.....	81	Namenda	86
Lorazepam Intensol.....	53	Namenda Titration Pak	86
lorazepam oral tablet.....	53	Namenda XR.....	86
Lupron Depot	78	Natpara.....	87
Lupron Depot (3 Month).....	78	Nebupent.....	170
Lupron Depot (4 Month).....	78	Neoral.....	170
Lupron Depot (6 Month).....	78	Nephramine 5.4 %	170
Lupron Depot-Ped intramuscular kit 11.25 mg, 15 mg	78	Neupogen	88
Lynparza	82	Neupro.....	89
M		Nexavar	90
magnesium sulfate	170	Ninlaro	91
megestrol oral suspension 400 mg/10 mL (40 mg/mL), 625 mg/5 mL	83	nitroglycerin.....	170
		Norditropin FlexPro	49
		Normosol-M in 5 % dextrose.....	170
		Normosol-R in 5 % dextrose.....	170
		Normosol-R pH 7.4.....	170

Northera	92	potassium chloride-D5-0.9%NaCl.....	171
Novarel.....	22	Potiga	108
Nulojix	170	Praluent Pen subcutaneous pen injector	150
Nuplazid.....	93	mg/mL, 75 mg/mL.....	109
O		Praluent Syringe subcutaneous syringe	150
octreotide acetate injection solution.....	95	mg/mL, 75 mg/mL.....	109
Odomzo.....	96	Pregnyl	22
Ofev.....	97	Premarin.....	171
ondansetron	170	Premasol 10 %	171
ondansetron HCl	170	Premasol 6 %	171
ondansetron HCl (PF)	170	Procalamine 3%	171
Onfi oral suspension	98	Procrit injection solution 10,000 unit/mL,	
Onfi oral tablet 10 mg, 20 mg.....	98	2,000 unit/mL, 20,000 unit/mL, 3,000	
Opdivo intravenous solution 40 mg/4 mL	99	unit/mL, 4,000 unit/mL, 40,000 unit/mL	
Opsumit.....	100	111
Orkambi	101	Proleukin.....	171
oxaliplatin	170	Prolia.....	113
oxazepam	53	Promacta	115
P		promethazine oral tablet.....	52
paclitaxel.....	170	propranolol.....	171
pamidronate.....	170	Prosol 20 %	171
paricalcitol.....	170	Pulmozyme	171
Pegasys subcutaneous solution	102	Q	
Pegasys subcutaneous syringe	102	quinine sulfate.....	116
PegIntron.....	103	R	
PegIntron Redipen	103	ranitidine HCl.....	171
penicillin G potassium	170	Rapamune	171
penicillin G sodium.....	170	Ravicti.....	117
Pentam.....	170	Rebif (with albumin).....	118
Perforomist.....	170	Rebif Rebidoso subcutaneous pen injector	
Perjeta	105	22 mcg/0.5 mL, 44 mcg/0.5 mL,	
perphenazine-amitriptyline	55	8.8mcg/0.2mL-22 mcg/0.5mL (6)	118
phenobarbital.....	55	Rebif Titration Pack.....	118
phenoxybenzamine	106	Recombivax HB (PF).....	171
phenytoin sodium.....	170	Remicade.....	119
piperacillin-tazobactam.....	170	Remodulin.....	171
Plasma-Lyte 148	170	Repatha SureClick	121
Plasma-Lyte A	170	Repatha Syringe	121
Plasma-Lyte-56 in 5 % dextrose.....	171	reserpine.....	52
Pomalyst.....	107	Revlimid.....	124
potassium chlorid-D5-0.45%NaCl.....	171	ribavirin oral capsule.....	125
potassium chloride in 0.9%NaCl	171	ribavirin oral tablet 200 mg.....	125
potassium chloride in 5 % dex	171	rifampin.....	171
potassium chloride in LR-D5.....	171	ringers	171
potassium chloride-D5-0.2%NaCl.....	171	Risperdal Consta.....	171
potassium chloride-D5-0.3%NaCl.....	171	Rituxan.....	126

S

Sabril 127
 Samsca oral tablet 15 mg, 30 mg 128
 Sancuso 171
 Sandimmune 171
 Sandostatin LAR Depot intramuscular
 suspension,extended rel recon 129
 Signifor 130
 sildenafil oral 123
 Simulect 171
 sirolimus..... 171
 Solu-Cortef (PF)..... 171
 Somatuline Depot..... 171
 Somavert 171
 Sovaldi 131
 Sprycel oral tablet 100 mg, 140 mg, 20 mg,
 50 mg, 70 mg, 80 mg 132
 Stivarga 133
 streptomycin..... 171
 sulfamethoxazole-trimethoprim 171
 Surmontil..... 55
 Sutent 134
 Sylatron 135
 Synagis intramuscular solution 50 mg/0.5
 mL..... 136
 Synercid 171
 Synribo 171

T

tacrolimus..... 171
 Tafenlar..... 138
 Tagrisso..... 139
 Tarceva oral tablet 100 mg, 150 mg, 25 mg
 140
 Tasigna..... 142
 Tecentriq 143
 Teflaro..... 171
 temazepam 53
 testosterone cypionate..... 171
 testosterone enanthate 171
 tetanus-diphtheria toxoids-Td 171
 tetrabenazine 144
 Thalomid 145
 thioridazine 146
 thiotepa..... 147
 tobramycin in 0.225 % NaCl 171
 tobramycin sulfate..... 171

topiramate oral capsule, sprinkle 10
 topiramate oral capsule,sprinkle,ER 24hr. 10
 topiramate oral tablet 10
 Toposar 171
 topotecan 171
 tranexamic acid 171
 Travasol 10 % 171
 Treanda 171
 Trelstar 171
 tretinoin microspheres topical gel with pump
 149
 tretinoin topical 149
 trihexyphenidyl 52
 trimipramine..... 55
 Trisenox 171
 TrophAmine 10 %..... 171
 Trophamine 6%..... 171
 Twinrix (PF)..... 171
 Tykerb 150
 Tysabri 151
 Tyvaso..... 153

U

Uptravi oral tablet 154
 Uptravi oral tablets,dose pack..... 154

V

valproate sodium..... 171
 vancomycin 171
 Varubi 171
 Velcade 171
 Venclexta 155
 Venclexta Starting Pack 155
 verapamil..... 171
 Vimpat intravenous 156
 Vimpat oral solution 156
 Vimpat oral tablet 156
 vinblastine 171
 Vincasar PFS..... 171
 vincristine..... 171
 vinorelbine 171
 Virazole..... 171
 voriconazole 171
 Votrient 157
 VPRIV..... 171

X

Xalkori 158
 Xgeva 171

Xolair	159
Xtandi.....	160
Y	
Yervoy intravenous solution 50 mg/10 mL (5 mg/mL).....	161
Z	
Zaltrap intravenous solution 100 mg/4 mL (25 mg/mL).....	162
Zelboraf.....	163
Zemplar	171

zoledronic acid.....	171
zoledronic acid-mannitol-water intravenous solution.....	164
Zometa	171
zonisamide	10
Zortress	171
Zydelig	166
Zykadia	167
Zyprexa Relprevv.....	171



ConnectiCare, Inc. is an HMO/HMO-POS plan with a Medicare contract. Enrollment in ConnectiCare depends on contract renewal.

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

Beneficiaries must use network pharmacies to access their premium and/or copayment/coinsurance may change on January 1, 2018

This document includes ConnectiCare VIP Medicare Plan's partial formulary as of August 23, 2016. For a complete, updated formulary, please visit our website at www.connecticare.com/Medicare or call the Member Services number below. For alternative formats or language, please call Member Services toll free at:

1-800-CCI-CARE (1-800-224-2273) between the hours of 8:00 a.m. and 8:00 p.m., seven days a week.

TTY/TDD users should call 1-800-842-9710.

17204 v8